Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

Leukemia volume 28, pages 928–934 (2014)Cite this article

Subjects

Abstract

We prospectively evaluated the effect of bortezomib, thalidomide and dexamethasone (VTD) consolidation on bone metabolism of 42 myeloma patients who underwent an autologous stem cell transplantation (ASCT). VTD started on day 100 post ASCT; patients received four cycles of VTD (first block), were followed without treatment for 100 days and then received another four VTD cycles (second block). During this 12-month period, bisphosphonates were not administered. Best response included stringent complete remission (sCR) in 15 (35.7%) patients, complete response (CR) in 13 (30.9%), vgPR in 7 (16.6%), PR in 4 (9.5%), while 3 (7.1%) patients developed a progressive disease (PD). Importantly, 33.3% and 47.6% of patients improved their status of response after the first and second VTD block, respectively. VTD consolidation resulted in a significant reduction of circulating C-terminal cross-linking telopeptide of collagen type I (CTX), soluble receptor activator of the nuclear factor-kappa B ligand (sRANKL) and osteocalcin (OC), whereas bone-specific alkaline phosphatase (bALP) remained stable compared with pre-VTD values. During the study period, only one patient with a PD developed a skeletal-related event (that is, radiation to bone). The median time to progression (TTP) after ASCT was 34 months and the median time of next treatment was 40 months. We conclude that VTD consolidation post ASCT reduces bone resorption and is associated with a very low incidence of skeletal-related events (SREs) despite the absence of bisphosphonates; the later do not appear to be necessary in this context.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220–1227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chrétien ML et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTdinduction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013; 27: 2242–2244.

    Article  CAS  PubMed  Google Scholar 

  3. Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL et al. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Ann Hematol 2012; 91: 249–256.

    Article  CAS  PubMed  Google Scholar 

  4. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 1597–1600.

    Article  Google Scholar 

  5. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077–2084.

    Article  CAS  PubMed  Google Scholar 

  6. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688–692.

    Article  CAS  PubMed  Google Scholar 

  7. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010; 21: 1561–1562.

    Article  CAS  PubMed  Google Scholar 

  8. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated withbortezomib response in multiple myeloma patients. Haematologica 2011; 96: 333–336.

    Article  CAS  PubMed  Google Scholar 

  9. Terpos E, Morgan G, Dimopoulos M, Drake M, Lentzsch S, Raje N et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma related bone disease. J Clin Oncol 2013; 31: 2347–2357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247–2256.

    Article  CAS  PubMed  Google Scholar 

  11. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012; 5: CD003188.

    Google Scholar 

  12. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD . Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000; 96: 2697–2702.

    CAS  PubMed  Google Scholar 

  13. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420–1426.

    Article  CAS  PubMed  Google Scholar 

  14. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119: 1728–1731.

    Article  CAS  PubMed  Google Scholar 

  15. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969–1976.

    Article  CAS  PubMed  Google Scholar 

  16. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006; 76: 399–404.

    Article  CAS  PubMed  Google Scholar 

  17. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009; 13: 839–848.

    Article  CAS  PubMed  Google Scholar 

  18. Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011; 86: 372–384.

    Article  CAS  PubMed  Google Scholar 

  19. Chanan-Khan AA, Giralt S . Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612–2624.

    Article  CAS  PubMed  Google Scholar 

  20. Harousseau JL, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139–3146.

    Article  CAS  PubMed  Google Scholar 

  21. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770–1781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

    E Terpos, D Christoulas, E Kastritis, M Roussou, M Migkou, E Eleutherakis-Papaiakovou, M Gavriatopoulou, M Gkotzamanidou, N Kanellias, E Manios, C Papadimitriou & M A Dimopoulos

Authors
  1. E Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Christoulas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Kastritis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Roussou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Migkou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Eleutherakis-Papaiakovou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Gavriatopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Gkotzamanidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Kanellias
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Manios
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M A Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Terpos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terpos, E., Christoulas, D., Kastritis, E. et al. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia 28, 928–934 (2014). https://doi.org/10.1038/leu.2013.267

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.267

Keywords

This article is cited by

Search

Advanced search

Quick links